Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic

Charles A. Kunos; Molly E. Martin; Michalis F. Georgiou; Russ A. Kuker; Aman Chauhan

doi:10.3390/cancers16071396

Back

Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic

Journal article

Open access

Peer reviewed

Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic

Charles A. Kunos, Molly E. Martin, Michalis F. Georgiou, Russ A. Kuker and Aman Chauhan

Cancers, Vol.16(7), 1396

04/01/2024

DOI: 10.3390/cancers16071396

PMID: 38611074

Files and links (1)

url

https://doi.org/10.3390/cancers16071396View

Published (Version of record) Open Access

Abstract

Simple Summary Until recently, radiopharmaceuticals have been underutilized for the curative or the palliative treatment of cancer. Advances in a development program with investigational agents that have a radioactive payload as part of the studied drug product necessitate new ways of drug handling and administration as well as novel logistics for a safe and satisfactory patient experience. This review offers a roadmap for the clinical start-up and implementation of an integrated and leveraged programmatic collaboration for an academic theranostic center. Within this roadmap, there are complex issues of logistics, coordination, medical considerations, radioprotection, receipt and waste of radioactive agents, and patient release priorities. Regulatory agency input also adds to the layout dynamics of the theranostic center, but this roadmap does not cover specific requirements as United States state laws differ considerably. Abstract Radiation oncologists, radiopharmacists, nuclear medicine physicians, and medical oncologists have seen a renewed clinical interest in radiopharmaceuticals for the curative or the palliative treatment of cancer. To allow for the discovery and the clinical advancement of targeted radiopharmaceuticals, these stakeholders have reformed their trial efforts and remodeled their facilities to accommodate the obligations of a program centered upon radioactive investigational drug products. Now considered informally as drugs and not beam radiotherapy, radiopharmaceuticals can be more easily studied in the traditional clinical trial enterprise ranging from phase 0–I to phase III studies. Resources and physical facilities allocated to radiopharmaceuticals have brought forth new logistics and patient experience for safe and satisfactory drug delivery. The clinical use of theranostic agents—that is, diagnostic and therapeutic radionuclide pairs—has accelerated radiopharmaceutical development.

floor plan

radionuclide treatment

radiopharmaceutical

theranostic

theranostic center

Details

Title: Subtitle: Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic
Creators: Charles A. Kunos - Sylvester Comprehensive Cancer Center
Molly E. Martin - University of Iowa Health Care
Michalis F. Georgiou - University of Miami
Russ A. Kuker - University of Miami
Aman Chauhan - University of Miami
Resource Type: Journal article
Publication Details: Cancers, Vol.16(7), 1396
DOI: 10.3390/cancers16071396
PMID: 38611074
NLM abbreviation: Cancers (Basel)
ISSN: 2072-6694
eISSN: 2072-6694
Publisher: MDPI
Grant note: P30 CA240139-01 / Center for Strategic Scientific Initiatives, National Cancer Institute (100008637) P30 CA240139-01 / National Cancer Institute (100000054) National Cancer Institute (http://data.elsevier.com/vocabulary/SciValFunders/100000054) P30 CA240139-01 / National Cancer Institute, Cairo University (501100002387) University of Miami Sylvester Comprehensive Cancer Center P30 CA240139-01 / National Cancer Institute (http://data.elsevier.com/vocabulary/SciValFunders/100000054) P30 CA240139-01 / Division of Cancer Prevention, National Cancer Institute (100007316) P30 CA240139-01 / National Computational Infrastructure (100010582)
Language: English
Date published: 04/01/2024
Academic Unit: Radiology
Record Identifier: 9985217812502771

Metrics

5 Record Views

2 Times Cited - Web of Science